Olema Pharmaceuticals granted 124,000 stock options to four new employees, effective September 2, 2025, under its 2022 Inducement Plan.
Quiver AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, announced the grant of stock options to four new employees for a total of 124,000 shares of common stock, effective September 2, 2025. This grant was approved by Olema's Compensation Committee under the 2022 Inducement Plan, aligning with Nasdaq rules. The stock options vest over four years, with an exercise price of $6.47 per share, based on the last reported sale price. Olema is advancing innovative cancer therapies, including its lead candidate, palazestrant, currently in a Phase 3 trial, and is headquartered in San Francisco with additional operations in Cambridge, Massachusetts.
Potential Positives
- Olema Pharmaceuticals has granted stock options to four new employees, indicating growth and expansion as the company adds talent to its team.
- The stock options are granted under the 2022 Inducement Plan, demonstrating Olema's commitment to attracting and retaining skilled professionals in the biopharmaceutical industry.
- With a pipeline focused on innovative therapies for breast cancer, including a lead candidate in a Phase 3 clinical trial, Olema is actively advancing its research and development efforts.
- The exercise price of the stock options is aligned with the company's current stock value, reflecting a fair valuation and potential for growth as the company progresses in its clinical trials.
Potential Negatives
- Granting stock options to only four new employees, rather than a larger cohort, could indicate limitations in the company's hiring and growth potential.
- The relatively modest amount of stock options (124,000 shares) may signal underlying concerns regarding employee retention and motivation in a highly competitive market for talent.
- Stock options being tied to continued employment may raise concerns about employee turnover and the company's ability to retain talent in the long term.
FAQ
What recent stock options were granted by Olema Pharmaceuticals?
Olema Pharmaceuticals granted stock options to four new employees, totaling 124,000 shares, effective September 2, 2025.
What is the vesting schedule for the stock options?
The stock options vest over four years, with 25% vesting on the first anniversary and the rest in monthly installments.
What is the exercise price of the stock options granted?
The exercise price of the stock options is $6.47 per share, matching the last reported sale price on September 2, 2025.
What are Olema Pharmaceuticals' main research focuses?
Olema focuses on targeted therapies for breast cancer and is advancing novel treatments for endocrine-driven cancers.
Where is Olema Pharmaceuticals headquartered?
Olema Pharmaceuticals is headquartered in San Francisco, with operations also in Cambridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Hedge Fund Activity
We have seen 71 institutional investors add shares of $OLMA stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,022,784 shares (+inf%) to their portfolio in Q2 2025, for an estimated $12,877,059
- WOODLINE PARTNERS LP added 2,027,986 shares (+137.2%) to their portfolio in Q2 2025, for an estimated $8,639,220
- AVORO CAPITAL ADVISORS LLC removed 1,651,982 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,211,452
- POINT72 ASSET MANAGEMENT, L.P. removed 1,441,690 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,141,599
- WELLINGTON MANAGEMENT GROUP LLP removed 1,245,658 shares (-84.5%) from their portfolio in Q2 2025, for an estimated $5,306,503
- MORGAN STANLEY added 985,716 shares (+218.2%) to their portfolio in Q2 2025, for an estimated $4,199,150
- BLACKROCK, INC. added 782,767 shares (+20.5%) to their portfolio in Q2 2025, for an estimated $3,334,587
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 08/12/2025
- Goldman Sachs issued a "Buy" rating on 05/14/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/28/2025
- JP Morgan issued a "Overweight" rating on 03/28/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 5 analysts offer price targets for $OLMA in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Matthew Biegler from Oppenheimer set a target price of $22.0 on 09/03/2025
- Anupam Rama from JP Morgan set a target price of $29.0 on 08/14/2025
- Yigal Nochomovitz from Citigroup set a target price of $21.0 on 08/12/2025
- Richard Law from Goldman Sachs set a target price of $18.0 on 05/14/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $30.0 on 04/28/2025
Full Release
SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 124,000 shares of the Company's common stock, effective as of September 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $6.47 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
